News|Videos|July 11, 2024
Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis
Key opinion leaders share their approach to treatment sequencing for patients with multiple sclerosis (MS), taking into account comorbidities such as cardiovascular diseases, risk of infection, liver damage, and cancer as well as considering factors like planned pregnancy or advanced age.
Advertisement
Episodes in this series
- How do you choose between different therapies for moderate MS in the context of other conditions?
- Patients with comorbidities (eg, cardiovascular diseases, risk of infection, liver damage, cancer)
- Patients considering pregnancy in the near future
- Patients who have late onset MS or are older
Advertisement
Related to this article
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
2
AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS
3
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
4
Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
5